Sep 2026· Essays in Biochemistry· 0 citations· 88 references
Medicine
Abstract
Proteolysis-targeting chimeras (PROTACs) have emerged as a powerful class of chemical probes that degrade rather than inhibit target proteins, thus expanding the tools for studying protein function in cells. PROTACs trigger catalytic and sub-stoichiometric degradation of the target protein in contrast with stoichiometric, occupancy-based inhibition. Because of this distinct mode of action, PROTACs overcome key limitations of inhibitors, including incomplete functional suppression, the requirement for sustained target occupancy, and poor selectivity within conserved protein families. PROTAC activity depends on multiple factors, including cell permeability, binary target engagement, ternary complex formation, stability and cooperativity, and efficiency of ubiquitination and degradation. Robust evaluation of PROTAC chemical probes therefore requires systematic assessment of potency, degradation kinetics, mechanistic validation, and selectivity profiling. Advances in mechanistic understanding have positioned PROTACs as versatile chemical probes that enable precise and temporally controlled protein depletion, offering unique opportunities for target validation, pathway dissection, and drug discovery. Recent case studies demonstrate clinical and preclinical PROTACs targeting previously undruggable proteins, highlighting the potential of degradation strategies, while emerging modalities such as molecular glues and proximity-inducing molecules further broaden the landscape of protein regulation.
This review summarizes recent advances in chemical protein degradation strategies for neurodegenerative disorders and highlights potential future perspectives of multifunctional PROTACs for therapeutic development.
Pasquale Degennaro, Imane Ghafir El Idrissi, Rosa Purgatorio et al.· Pharmaceuticals· 0 citations
Advances establish PROTAC technology as a transformative platform in modern drug discovery while emphasizing the scientific and translational challenges that must be addressed to enable broader clinical application.
S. Badadhe, Vikas B. Gawali, Mahesh D. Bhalsing et al.· Discover Chemistry· 0 citations
The molecular mechanisms, recent advances, and emerging applications of bioPROTAC technology are summarized, the current technical challenges are evaluated, potential strategies to address these limitations are discussed, and future directions that may facilitate its clinical translation are highlighted.
Proteolysis-targeting chimeras (PROTACs) are promising anticancer agents, but optimizing them requires screening strategies that go beyond simple target-degradation readouts. This review provides an overview of assays for evaluating anticancer PROTACs and classifies them by their role in the degradation pathway, includ...
Raghd Obidat, Jazmin Reyes-Martinez, Sara Alrawashdeh et al.· Drug Discovery Today· 0 citations
This chapter systematically examines three progressive tiers of PROTAC delivery using stimuli-activatable moieties, and highlights how these strategies achieve spatiotemporally controlled, tumor-selective protein degradation while minimizing off-tumor toxicity.
Yi-Jing Dang, Ze-Li Long, Jing Gao et al.· Handbook of Experimental Pha...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.